Austrianni leverages the powerful Trianni platform to isolate fully human antibodies designed to inactivate or kill target bacteria. This platform enables natural antibody diversity through V(D)J recombination and somatic hypermutation. We use it in our hybridoma pipeline or directly select antibody-producing plasma cells. Additionally, we develop antibodies with extended CDR3 loops, allowing better access to hidden bacterial structures or enzymatic active sites.

Using sophisticated immunization and selection methods, we are developing neutralizing and lysing antibodies to common surface structures of the bacterial strains that are responsible for the majority of the extraintestinal infections.